Stock SLRX SALARIUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Salarius Pharmaceuticals, Inc.

Equities

SLRX

US79400X3052

Market Closed - Nasdaq
Other stock markets
 21:30:00 15/05/2024 BST 		5-day change 1st Jan Change
0.458 USD +0.64% Intraday chart for Salarius Pharmaceuticals, Inc. -5.99% -29.54%
03-25 Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data MT
03-25 Top Premarket Gainers MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Salarius: Q1 Earnings Snapshot
AQ
Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data
MT
Top Premarket Gainers
MT
North American Morning Briefing : Tech in Focus on -2-
DJ
Salarius: Q4 Earnings Snapshot
AQ
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
AQ
Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
CI
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
AQ
Salarius Pharmaceuticals, Inc. Announces Update on Hematologic Cancer Phase 1/2 Clinical Trial Be Conducted At the University of Texas MD Anderson Cancer Center
CI
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
AQ
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)
AQ
North American Morning Briefing : Stock Futures -2-
DJ
Salarius: Q3 Earnings Snapshot
AQ
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
AQ
Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
CI
Salarius: Q2 Earnings Snapshot
AQ
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLRX Stock
  4. News Salarius Pharmaceuticals, Inc.